Identifying breast cancer patients at high risk for bone metastases

M. Colleoni, A. O'Neill, A. Goldhirsch, R. D. Gelber, M. Bonetti, B. Thurlimann, K. N. Price, M. Castiglione-Gertsch, A. S. Coates, J. Lindtner, J. Collins, H. J. Senn, F. Cavalli, J. Forbes, A. Gudgeon, E. Simoncini, H. Cortes-Funes, A. Veronesi, M. Fey, C. M. Rudenstam

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Purpose: To identify patient populations at high risk for bone metastases at any time after diagnosis of operable breast cancer, because these patients are potential beneficiaries of treatment with bisphosphonates. Patients and Methods: We evaluated data from 6,792 patients who were randomized in International Breast Cancer Study Group clinical trials between 1978 and 1993. Median follow-up was 10.7 years. A total of 1,275 patients (18.7%) presented with node-negative disease, whereas 3,354 patients (49.4%) had one to three and 2,163 patients (31.9%) had four or more involved axillary lymph nodes. We also assessed the incidence of subsequent bone metastases in the cohort of 1,220 patients who had a first event in local or regional sites or soft tissue alone. Median follow-up for this cohort was 7.7 years from first recurrence. I Results: For the entire population with operable disease, the cumulative incidence of bone metastases at any time was 8.2% at 2 years from randomization and 27.3% at 10 years. The highest cumulative incidences of bone metastases at any time were among patients who had four or more involved axillary nodes at the time of diagnosis (14.9% at 2 years and 40.8% at 10 years) and among patients who had as their first event a local or regional recurrence or a recurrence in soft tissue, without any other overt metastases (21.1% at 2 years from first recurrence and 36.7% at 10 years). Conclusion: Treatments to prevent bone metastases may have a major impact on the course of breast cancer and may be most efficiently studied in populations with several involved axillary nodes at the time of presentation and in populations with local or regional recurrence or recurrence in soft tissue. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish
Pages (from-to)3925
Number of pages1
JournalJournal of Clinical Oncology
Volume18
Issue number23
Publication statusPublished - Dec 1 2000

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Recurrence
Incidence
Population
Diphosphonates
Random Allocation
Lymph Nodes
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Colleoni, M., O'Neill, A., Goldhirsch, A., Gelber, R. D., Bonetti, M., Thurlimann, B., ... Rudenstam, C. M. (2000). Identifying breast cancer patients at high risk for bone metastases. Journal of Clinical Oncology, 18(23), 3925.

Identifying breast cancer patients at high risk for bone metastases. / Colleoni, M.; O'Neill, A.; Goldhirsch, A.; Gelber, R. D.; Bonetti, M.; Thurlimann, B.; Price, K. N.; Castiglione-Gertsch, M.; Coates, A. S.; Lindtner, J.; Collins, J.; Senn, H. J.; Cavalli, F.; Forbes, J.; Gudgeon, A.; Simoncini, E.; Cortes-Funes, H.; Veronesi, A.; Fey, M.; Rudenstam, C. M.

In: Journal of Clinical Oncology, Vol. 18, No. 23, 01.12.2000, p. 3925.

Research output: Contribution to journalArticle

Colleoni, M, O'Neill, A, Goldhirsch, A, Gelber, RD, Bonetti, M, Thurlimann, B, Price, KN, Castiglione-Gertsch, M, Coates, AS, Lindtner, J, Collins, J, Senn, HJ, Cavalli, F, Forbes, J, Gudgeon, A, Simoncini, E, Cortes-Funes, H, Veronesi, A, Fey, M & Rudenstam, CM 2000, 'Identifying breast cancer patients at high risk for bone metastases', Journal of Clinical Oncology, vol. 18, no. 23, pp. 3925.
Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B et al. Identifying breast cancer patients at high risk for bone metastases. Journal of Clinical Oncology. 2000 Dec 1;18(23):3925.
Colleoni, M. ; O'Neill, A. ; Goldhirsch, A. ; Gelber, R. D. ; Bonetti, M. ; Thurlimann, B. ; Price, K. N. ; Castiglione-Gertsch, M. ; Coates, A. S. ; Lindtner, J. ; Collins, J. ; Senn, H. J. ; Cavalli, F. ; Forbes, J. ; Gudgeon, A. ; Simoncini, E. ; Cortes-Funes, H. ; Veronesi, A. ; Fey, M. ; Rudenstam, C. M. / Identifying breast cancer patients at high risk for bone metastases. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 23. pp. 3925.
@article{94e6bef4311148749dde15290a0005a0,
title = "Identifying breast cancer patients at high risk for bone metastases",
abstract = "Purpose: To identify patient populations at high risk for bone metastases at any time after diagnosis of operable breast cancer, because these patients are potential beneficiaries of treatment with bisphosphonates. Patients and Methods: We evaluated data from 6,792 patients who were randomized in International Breast Cancer Study Group clinical trials between 1978 and 1993. Median follow-up was 10.7 years. A total of 1,275 patients (18.7{\%}) presented with node-negative disease, whereas 3,354 patients (49.4{\%}) had one to three and 2,163 patients (31.9{\%}) had four or more involved axillary lymph nodes. We also assessed the incidence of subsequent bone metastases in the cohort of 1,220 patients who had a first event in local or regional sites or soft tissue alone. Median follow-up for this cohort was 7.7 years from first recurrence. I Results: For the entire population with operable disease, the cumulative incidence of bone metastases at any time was 8.2{\%} at 2 years from randomization and 27.3{\%} at 10 years. The highest cumulative incidences of bone metastases at any time were among patients who had four or more involved axillary nodes at the time of diagnosis (14.9{\%} at 2 years and 40.8{\%} at 10 years) and among patients who had as their first event a local or regional recurrence or a recurrence in soft tissue, without any other overt metastases (21.1{\%} at 2 years from first recurrence and 36.7{\%} at 10 years). Conclusion: Treatments to prevent bone metastases may have a major impact on the course of breast cancer and may be most efficiently studied in populations with several involved axillary nodes at the time of presentation and in populations with local or regional recurrence or recurrence in soft tissue. (C) 2000 by American Society of Clinical Oncology.",
author = "M. Colleoni and A. O'Neill and A. Goldhirsch and Gelber, {R. D.} and M. Bonetti and B. Thurlimann and Price, {K. N.} and M. Castiglione-Gertsch and Coates, {A. S.} and J. Lindtner and J. Collins and Senn, {H. J.} and F. Cavalli and J. Forbes and A. Gudgeon and E. Simoncini and H. Cortes-Funes and A. Veronesi and M. Fey and Rudenstam, {C. M.}",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "18",
pages = "3925",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "23",

}

TY - JOUR

T1 - Identifying breast cancer patients at high risk for bone metastases

AU - Colleoni, M.

AU - O'Neill, A.

AU - Goldhirsch, A.

AU - Gelber, R. D.

AU - Bonetti, M.

AU - Thurlimann, B.

AU - Price, K. N.

AU - Castiglione-Gertsch, M.

AU - Coates, A. S.

AU - Lindtner, J.

AU - Collins, J.

AU - Senn, H. J.

AU - Cavalli, F.

AU - Forbes, J.

AU - Gudgeon, A.

AU - Simoncini, E.

AU - Cortes-Funes, H.

AU - Veronesi, A.

AU - Fey, M.

AU - Rudenstam, C. M.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Purpose: To identify patient populations at high risk for bone metastases at any time after diagnosis of operable breast cancer, because these patients are potential beneficiaries of treatment with bisphosphonates. Patients and Methods: We evaluated data from 6,792 patients who were randomized in International Breast Cancer Study Group clinical trials between 1978 and 1993. Median follow-up was 10.7 years. A total of 1,275 patients (18.7%) presented with node-negative disease, whereas 3,354 patients (49.4%) had one to three and 2,163 patients (31.9%) had four or more involved axillary lymph nodes. We also assessed the incidence of subsequent bone metastases in the cohort of 1,220 patients who had a first event in local or regional sites or soft tissue alone. Median follow-up for this cohort was 7.7 years from first recurrence. I Results: For the entire population with operable disease, the cumulative incidence of bone metastases at any time was 8.2% at 2 years from randomization and 27.3% at 10 years. The highest cumulative incidences of bone metastases at any time were among patients who had four or more involved axillary nodes at the time of diagnosis (14.9% at 2 years and 40.8% at 10 years) and among patients who had as their first event a local or regional recurrence or a recurrence in soft tissue, without any other overt metastases (21.1% at 2 years from first recurrence and 36.7% at 10 years). Conclusion: Treatments to prevent bone metastases may have a major impact on the course of breast cancer and may be most efficiently studied in populations with several involved axillary nodes at the time of presentation and in populations with local or regional recurrence or recurrence in soft tissue. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: To identify patient populations at high risk for bone metastases at any time after diagnosis of operable breast cancer, because these patients are potential beneficiaries of treatment with bisphosphonates. Patients and Methods: We evaluated data from 6,792 patients who were randomized in International Breast Cancer Study Group clinical trials between 1978 and 1993. Median follow-up was 10.7 years. A total of 1,275 patients (18.7%) presented with node-negative disease, whereas 3,354 patients (49.4%) had one to three and 2,163 patients (31.9%) had four or more involved axillary lymph nodes. We also assessed the incidence of subsequent bone metastases in the cohort of 1,220 patients who had a first event in local or regional sites or soft tissue alone. Median follow-up for this cohort was 7.7 years from first recurrence. I Results: For the entire population with operable disease, the cumulative incidence of bone metastases at any time was 8.2% at 2 years from randomization and 27.3% at 10 years. The highest cumulative incidences of bone metastases at any time were among patients who had four or more involved axillary nodes at the time of diagnosis (14.9% at 2 years and 40.8% at 10 years) and among patients who had as their first event a local or regional recurrence or a recurrence in soft tissue, without any other overt metastases (21.1% at 2 years from first recurrence and 36.7% at 10 years). Conclusion: Treatments to prevent bone metastases may have a major impact on the course of breast cancer and may be most efficiently studied in populations with several involved axillary nodes at the time of presentation and in populations with local or regional recurrence or recurrence in soft tissue. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0034554804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034554804&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 3925

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 23

ER -